{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:49:15Z","timestamp":1790682555798,"version":"4.1.0"},"reference-count":105,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deanship of Scientific Research at the Imam Mohammad Ibn Saud Islamic University (IMSIU)","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The discovery of effective therapeutics against Alzheimer\u2019s disease (AD) and other neurological disorders remains a significant challenge. Artificial intelligence (AI) tools are of considerable interest in modern drug discovery processes and, by exploiting machine learning (ML) algorithms and deep learning (DL) tools, as well as data analytics, can expedite the identification of new drug targets and potential lead molecules. The current study was aimed at assessing the role of AI-based tools in the discovery of new drug targets against AD and other related neurodegenerative diseases and their efficacy in the discovery of new drugs against these diseases. AD represents a multifactorial neurological disease with limited therapeutics available for management and limited efficacy. The discovery of more effective medications is limited by the complicated pathophysiology of the disease, involving amyloid beta (A\u03b2), neurofibrillary tangles (NFTs), oxidative stress, and inflammation-induced damage in the brain. The integration of AI tools into the traditional drug discovery process against AD can help to find more effective, safe, highly potent compounds, identify new targets of the disease, and help in the optimization of lead molecules. A detailed literature review was performed to gather evidence regarding the most recent AI tools for drug discovery against AD, Parkinson\u2019s disease (PD), multiple sclerosis (MLS), and epilepsy, focusing on biological markers, early diagnoses, and drug discovery using various databases like PubMed, Web of Science, Google Scholar, Scopus, and ScienceDirect to collect relevant literature. We evaluated the role of AI in analyzing multifaceted biological data and the properties of potential drug candidates and in streamlining the design of clinical trials. By exploring the intersection of AI and neuroscience, this review focused on providing insights into the future of AD treatment and the potential of AI to revolutionize the field of drug discovery. Our findings conclude that AI-based tools are not only cost-effective, but the success rate is extremely high compared to traditional drug discovery methods in identifying new therapeutic targets and in the screening of the majority of molecules for clinical trial purposes.<\/jats:p>","DOI":"10.3390\/ph18071041","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T09:56:54Z","timestamp":1752487014000},"page":"1041","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["From Molecules to Medicines: The Role of AI-Driven Drug Discovery Against Alzheimer\u2019s Disease and Other Neurological Disorders"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0706-7238","authenticated-orcid":false,"given":"Mashael A.","family":"Alghamdi","sequence":"first","affiliation":[{"name":"Department of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11432, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"The drug discovery process","volume":"62","author":"Herrling","year":"2005","journal-title":"Imaging Drug Discov. Early Clin. Trials"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.22270\/ajprd.v7i6.616","article-title":"The stages of drug discovery and development process","volume":"7","author":"Deore","year":"2019","journal-title":"Asian J. Pharm. Res. Dev."},{"key":"ref_4","first-page":"1","article-title":"Where traditional drug discovery meets modern technology in the quest for new drugs","volume":"2","author":"Alzahrani","year":"2017","journal-title":"Ann. Pharmacol. Pharm."},{"key":"ref_5","unstructured":"Ravina, E. (2011). The Evolution of Drug Discovery: From Traditional Medicines to Modern Drugs, John Wiley & Sons."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.drudis.2018.11.014","article-title":"Artificial intelligence in drug development: Present status and future prospects","volume":"24","author":"Mak","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.gpb.2017.07.003","article-title":"Deep learning and its applications in biomedicine","volume":"16","author":"Cao","year":"2018","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41587-019-0224-x","article-title":"Deep learning enables rapid identification of potent DDR1 kinase inhibitors","volume":"37","author":"Zhavoronkov","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10822-016-9938-8","article-title":"Molecular graph convolutions: Moving beyond fingerprints","volume":"30","author":"Kearnes","year":"2016","journal-title":"J. Comput. -Aided Mol. Des."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: The pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mrazek, M., and O\u2019Neill, F. (2020). Artificial Intelligence and Healthcare in Emerging Markets, World Bank Group.","DOI":"10.1596\/34855"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Al Kuwaiti, A., Nazer, K., Al-Reedy, A., Al-Shehri, S., Al-Muhanna, A., Subbarayalu, A.V., Al Muhanna, D., and Al-Muhanna, F.A. (2023). A review of the role of artificial intelligence in healthcare. J. Pers. Med., 13.","DOI":"10.3390\/jpm13060951"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nrd1202","article-title":"Target discovery","volume":"2","author":"Lindsay","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd1086","article-title":"Hit and lead generation: Beyond high-throughput screening","volume":"2","author":"Bleicher","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1038\/d41586-018-05267-x","article-title":"How artificial intelligence is changing drug discovery","volume":"557","author":"Fleming","year":"2018","journal-title":"Nature"},{"key":"ref_20","first-page":"44","article-title":"Integrating AI and Deep Learning for Efficient Drug Discovery and Target Identification","volume":"2","author":"Huang","year":"2024","journal-title":"J. AI-Powered Med. Innov."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Crucitti, D., P\u00e9rez M\u00edguez, C., D\u00edaz Arias, J.\u00c1., Fernandez Prada, D.B., and Mosquera Orgueira, A. (2024). De novo drug design through artificial intelligence: An introduction. Front. Hematol., 3.","DOI":"10.3389\/frhem.2024.1305741"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7761","DOI":"10.1038\/s41467-024-52061-7","article-title":"An artificial intelligence accelerated virtual screening platform for drug discovery","volume":"15","author":"Zhou","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/ar800236t","article-title":"Efficient drug lead discovery and optimization","volume":"42","author":"Jorgensen","year":"2009","journal-title":"Acc. Chem. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1021\/acs.jcim.3c00200","article-title":"Artificial intelligence in drug toxicity prediction: Recent advances, challenges, and future perspectives","volume":"63","author":"Tran","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Serrano, D.R., Luciano, F.C., Anaya, B.J., Ongoren, B., Kara, A., Molina, G., Ramirez, B.I., S\u00e1nchez-Guirales, S.A., Simon, J.A., and Tomietto, G. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16101328"},{"key":"ref_26","unstructured":"Walker, R. (2011). Clinical Pharmacy and Therapeutics E-Book, Elsevier Health Sciences."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s12525-021-00475-2","article-title":"Machine learning and deep learning","volume":"31","author":"Janiesch","year":"2021","journal-title":"Electron. Mark."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1126\/science.aaa8415","article-title":"Machine learning: Trends, perspectives, and prospects","volume":"349","author":"Jordan","year":"2015","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10542","DOI":"10.1021\/acs.jpcb.3c05521","article-title":"Graph Neural Networks and Structural Information on Ionic Liquids: A Cheminformatics Study on Molecular Physicochemical Property Prediction","volume":"127","author":"Baran","year":"2023","journal-title":"J. Phys. Chem. B"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13321-020-00479-8","article-title":"Could graph neural networks learn better molecular representation for drug discovery? A comparison study of descriptor-based and graph-based models","volume":"13","author":"Jiang","year":"2021","journal-title":"J. Cheminformatics"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhang, T., Guo, X., Chen, H., Fan, S., Li, Q., Chen, S., Guo, X., and Zheng, H. (2022). TG-GNN: Transformer based Geometric enhancement graph neural network for molecular property prediction. Res. Sq., preprint.","DOI":"10.21203\/rs.3.rs-1795724\/v1"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhang, P., Yan, Y., Zhang, X., Li, C., Wang, S., Huang, F., and Kim, S. (2024, January 14\u201318). TransGNN: Harnessing the collaborative power of transformers and graph neural networks for recommender systems. Proceedings of the 47th International ACM SIGIR Conference on Research and Development in Information Retrieval, Washington, DC, USA.","DOI":"10.1145\/3626772.3657721"},{"key":"ref_34","unstructured":"Su, Y., Lu, Z., Liu, J., Pang, K., Dai, H., Jia, S.L.Y., Ge, L., and Yang, J.-m. (2025). Applications of large models in medicine. arXiv."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Borkakoti, N., and Thornton, J.M. (2023). AlphaFold2 protein structure prediction: Implications for drug discovery. Curr. Opin. Struct. Biol., 78.","DOI":"10.1016\/j.sbi.2022.102526"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103551","DOI":"10.1016\/j.drudis.2023.103551","article-title":"AlphaFold, allosteric, and orthosteric drug discovery: Ways forward","volume":"28","author":"Nussinov","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1021\/acs.jcim.3c01459","article-title":"Alphafold2 in molecular discovery","volume":"63","author":"Merz","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Blanco-Gonzalez, A., Cabezon, A., Seco-Gonzalez, A., Conde-Torres, D., Antelo-Riveiro, P., Pineiro, A., and Garcia-Fandino, R. (2023). The role of AI in drug discovery: Challenges, opportunities, and strategies. Pharmaceuticals, 16.","DOI":"10.3390\/ph16060891"},{"key":"ref_39","first-page":"40","article-title":"AI Takes On Drug Discovery: From target screening to image analysis, companies are using machine learning tools to explore the unknown","volume":"43","author":"May","year":"2023","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"ref_40","unstructured":"Mamidala, S. (2023). NeuroCADR: Drug Repurposing to Reveal Novel Anti-Epileptic Drug Candidates Through an Integrated Computational Approach. arXiv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trci.2016.09.002","article-title":"Multiple comorbid neuropathologies in the setting of Alzheimer\u2019s disease neuropathology and implications for drug development","volume":"3","author":"Rabinovici","year":"2017","journal-title":"Alzheimer\u2019s Dement. Transl. Res. Clin. Interv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1359-6446(05)03680-9","article-title":"The promise of a virtual lab in drug discovery","volume":"11","author":"Rauwerda","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.1016\/j.csbj.2022.08.034","article-title":"Obtaining protein foldability information from computational models of AlphaFold2 and RoseTTAFold","volume":"20","author":"Liu","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Abduljawad, A.A., Elawad, M.A., Elkhalifa, M.E.M., Ahmed, A., Hamdoon, A.A.E., Salim, L.H.M., Ashraf, M., Ayaz, M., Hassan, S.S.u., and Bungau, S. (2022). Alzheimer\u2019s disease as a major public health concern: Role of dietary saponins in mitigating neurodegenerative disorders and their underlying mechanisms. Molecules, 27.","DOI":"10.3390\/molecules27206804"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"155272","DOI":"10.1016\/j.phymed.2023.155272","article-title":"Neuroprotective potentials of Lead phytochemicals against Alzheimer\u2019s disease with focus on oxidative stress-mediated signaling pathways: Pharmacokinetic challenges, target specificity, clinical trials and future perspectives","volume":"124","author":"Ayaz","year":"2024","journal-title":"Phytomedicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","article-title":"The global deterioration scale for assessment of primary degenerative dementia","volume":"139","author":"Reisburg","year":"1982","journal-title":"Am. J. Psychiatry"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","article-title":"The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence","volume":"10","author":"Barnes","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Mahnashi, M.H., Ashraf, M., Alhasaniah, A.H., Ullah, H., Zeb, A., Ghufran, M., Fahad, S., Ayaz, M., and Daglia, M. (2023). Polyphenol-enriched Desmodium elegans DC. ameliorate scopolamine-induced amnesia in animal model of Alzheimer\u2019s disease: In Vitro, In Vivo and In Silico approaches. Biomed. Pharmacother., 165.","DOI":"10.1016\/j.biopha.2023.115144"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"116786","DOI":"10.1016\/j.jep.2023.116786","article-title":"Quantitative-HPLC-DAD polyphenols analysis, anxiolytic and cognition enhancing potentials of Sorbaria tomentosa Lindl","volume":"317","author":"Mahnashi","year":"2023","journal-title":"Rehder. J. Ethnopharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e202203047","DOI":"10.1002\/slct.202203047","article-title":"Synthesis of spiro-oxindole analogs engrafted pyrazole scaffold as potential Alzheimer\u2019s disease therapeutics: Anti-oxidant, enzyme inhibitory and molecular docking approaches","volume":"7","author":"Yousuf","year":"2022","journal-title":"ChemistrySelect"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"105703","DOI":"10.1016\/j.fitote.2023.105703","article-title":"Neuroprotective evaluation of diospyrin against drug-induced Alzheimer\u2019s disease","volume":"171","author":"Alam","year":"2023","journal-title":"Fitoterapia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2400525","DOI":"10.1002\/mnfr.202400525","article-title":"Polyphenols and Their Biogenic Nano-Formulations Targeting BACE1 as Anti-Amyloid Therapies; Meeting the Challenges of Bioavailability, Safety, and Specificity for the Treatment of Alzheimer\u2019s Disease","volume":"68","author":"Elawad","year":"2024","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","article-title":"Alzheimer\u2019s disease: Clinical trials and drug development","volume":"9","author":"Mangialasche","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/s-0033-1359312","article-title":"Neuroimaging biomarkers of neurodegenerative diseases and dementia","volume":"33","author":"Risacher","year":"2013","journal-title":"Semin. Neurol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacr.2017.12.026","article-title":"Artificial intelligence and machine learning in radiology: Opportunities, challenges, pitfalls, and criteria for success","volume":"15","author":"Thrall","year":"2018","journal-title":"J. Am. Coll. Radiol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ficiar\u00e0, E., Boschi, S., Ansari, S., D\u2019Agata, F., Abollino, O., Caroppo, P., Di Fede, G., Indaco, A., Rainero, I., and Guiot, C. (2021). Machine learning profiling of Alzheimer\u2019s disease patients based on current cerebrospinal fluid markers and iron content in biofluids. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.607858"},{"key":"ref_57","first-page":"112","article-title":"Automatic speech analysis for the assessment of patients with predementia and Alzheimer\u2019s disease","volume":"1","author":"Satt","year":"2015","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1567205014666170829111942","article-title":"Use of speech analyses within a mobile application for the assessment of cognitive impairment in elderly people","volume":"15","author":"Konig","year":"2018","journal-title":"Curr. Alzheimer Res."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ritsner, M.S. (2009). The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes: Volume II: Neuroanatomical and Neuroimaging Endophenotypes and Biomarkers, Springer Science & Business Media.","DOI":"10.1007\/978-1-4020-9831-4"},{"key":"ref_60","first-page":"23","article-title":"Neuroimaging diagnosis in neurodegenerative diseases","volume":"13","author":"Markowicz","year":"2010","journal-title":"Nucl. Med. Rev."},{"key":"ref_61","first-page":"1778","article-title":"Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer\u2019s disease","volume":"47","author":"Mosconi","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.trsl.2018.01.001","article-title":"Use of multimodality imaging and artificial intelligence for diagnosis and prognosis of early stages of Alzheimer\u2019s disease","volume":"194","author":"Liu","year":"2018","journal-title":"Transl. Res."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Vrahatis, A.G., Skolariki, K., Krokidis, M.G., Lazaros, K., Exarchos, T.P., and Vlamos, P. (2023). Revolutionizing the early detection of Alzheimer\u2019s disease through non-invasive biomarkers: The role of artificial intelligence and deep learning. Sensors, 23.","DOI":"10.3390\/s23094184"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wolz, R., Julkunen, V., Koikkalainen, J., Niskanen, E., Zhang, D.P., Rueckert, D., Soininen, H., L\u00f6tj\u00f6nen, J., and Alzheimer\u2019s Disease Neuroimaging Initiative (2011). Multi-method analysis of MRI images in early diagnostics of Alzheimer\u2019s disease. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025446"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Zhang, T., Liao, Q., Zhang, D., Zhang, C., Yan, J., Ngetich, R., Zhang, J., Jin, Z., and Li, L. (2021). Predicting MCI to AD conversation using integrated sMRI and rs-fMRI: Machine learning and graph theory approach. Front. Aging Neurosci., 13.","DOI":"10.3389\/fnagi.2021.688926"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbe.2021.02.006","article-title":"Application of Artificial Intelligence techniques for the detection of Alzheimer\u2019s disease using structural MRI images","volume":"41","author":"Zhao","year":"2021","journal-title":"Biocybern. Biomed. Eng."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neuroimage.2012.09.058","article-title":"Prediction of Alzheimer\u2019s disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning","volume":"65","author":"Eskildsen","year":"2013","journal-title":"Neuroimage"},{"key":"ref_68","first-page":"29","article-title":"Application of artificial intelligence and machine learning techniques in classifying extent of dementia across Alzheimer\u2019s image data","volume":"6","author":"Ghosh","year":"2021","journal-title":"Int. J. Quant. Struct. Prop. Relatsh. (IJQSPR)"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neuroimage.2015.02.037","article-title":"Gaussian process classification of Alzheimer\u2019s disease and mild cognitive impairment from resting-state fMRI","volume":"112","author":"Challis","year":"2015","journal-title":"NeuroImage"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Li, Q., Wu, X., Xu, L., Chen, K., Yao, L., and Alzheimer\u2019s Disease Neuroimaging Initiative (2018). Classification of Alzheimer\u2019s disease, mild cognitive impairment, and cognitively unimpaired individuals using multi-feature kernel discriminant dictionary learning. Front. Comput. Neurosci., 11.","DOI":"10.3389\/fncom.2017.00117"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e2028634","DOI":"10.1001\/jamanetworkopen.2020.28634","article-title":"Assessment of plasma amyloid-\u03b242\/40 and cognitive decline among community-dwelling older adults","volume":"3","author":"Giudici","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer\u2019s disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_73","first-page":"443","article-title":"Developing an Artificial Intelligence Framework for Identifying Fusion Blood-Based Biomarkers in Alzheimer\u2019s Disease","volume":"10","author":"Nsaif","year":"2025","journal-title":"J. Inf. Syst. Eng. Manag."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e16089","DOI":"10.1111\/ene.16089","article-title":"Plasma neurofilament light chain predicts Alzheimer\u2019s disease in patients with subjective cognitive decline and mild cognitive impairment: A cross-sectional and longitudinal study","volume":"31","author":"Mazzeo","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/alz.12283","article-title":"The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease","volume":"17","author":"Leuzy","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3233\/JAD-190615","article-title":"Neurofilament light chain in cerebrospinal fluid and blood as a biomarker for neurodegenerative diseases: A systematic review and meta-analysis","volume":"72","author":"Wang","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12264-013-1410-3","article-title":"Lipid metabolism in Alzheimer\u2019s disease","volume":"30","author":"Liu","year":"2014","journal-title":"Neurosci. Bull."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.biopha.2007.05.009","article-title":"Serum biomarkers for Alzheimer\u2019s disease: Proteomic discovery","volume":"61","author":"German","year":"2007","journal-title":"Biomed. Pharmacother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.3233\/JAD-200305","article-title":"A community-based study identifying metabolic biomarkers of mild cognitive impairment and Alzheimer\u2019s disease using artificial intelligence and machine learning","volume":"78","author":"Yilmaz","year":"2020","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Yilmaz, A., Ugur, Z., Bisgin, H., Akyol, S., Bahado-Singh, R., Wilson, G., Imam, K., Maddens, M.E., and Graham, S.F. (2020). Targeted metabolic profiling of urine highlights a potential biomarker panel for the diagnosis of Alzheimer\u2019s disease and mild cognitive impairment: A pilot study. Metabolites, 10.","DOI":"10.3390\/metabo10090357"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Salvatore, C., Cerasa, A., Battista, P., Gilardi, M.C., Quattrone, A., Castiglioni, I., and Initiative, A.s.D.N. (2015). Magnetic resonance imaging biomarkers for the early diagnosis of Alzheimer\u2019s disease: A machine learning approach. Front. Neurosci., 9.","DOI":"10.3389\/fnins.2015.00307"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Nawaz, A., Sadiq, A., Bashir, N., Rashid, U., Ullah, F., Khan, S., Ullah, F., Khan, M.I., and Ayaz, M. (2025). Synthetic Derivates of Progesterone Ameliorate Scopolamine-Induced Cognitive Deficits in Animal Models: Antioxidant, Enzyme Inhibitory, Molecular Docking and Behavioral Correlates. Curr. Neuropharmacol., online ahead of print.","DOI":"10.2174\/011570159X357722250212094900"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: A powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"8359","DOI":"10.1080\/07391102.2023.2265494","article-title":"Phytochemicals-based \u03b2-amyloid cleaving enzyme-1 and MAO-B inhibitors for the treatment of Alzheimer\u2019s disease: Molecular simulations-based predictions","volume":"42","author":"Mahnashi","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1080\/07391102.2019.1704880","article-title":"In-silico design of peptide inhibitors of K-Ras target in cancer disease","volume":"38","author":"Ghufran","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ramakrishna, K., Karuturi, P., Siakabinga, Q., TA, G., Krishnamurthy, S., Singh, S., Kumari, S., Kumar, G.S., Sobhia, M.E., and Rai, S.N. (2024). Indole-3 carbinol and diindolylmethane mitigated \u03b2-amyloid-induced neurotoxicity and acetylcholinesterase enzyme activity: In silico, in vitro, and network pharmacology study. Diseases, 12.","DOI":"10.3390\/diseases12080184"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ghufran, M., Khan, H.A., Ullah, M., Ghufran, S., Ayaz, M., Siddiq, M., Hassan, S.S.u., and Bungau, S. (2022). In silico strategies for designing of peptide inhibitors of oncogenic K-ras G12V mutant: Inhibiting cancer growth and proliferation. Cancers, 14.","DOI":"10.3390\/cancers14194884"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ghufran, M., Ullah, M., Khan, H.A., Ghufran, S., Ayaz, M., Siddiq, M., Abbas, S.Q., Hassan, S.S.u., and Bungau, S. (2023). In-Silico lead druggable compounds identification against SARS COVID-19 main protease target from in-house, chembridge and zinc databases by structure-based virtual screening, molecular docking and molecular dynamics simulations. Bioengineering, 10.","DOI":"10.3390\/bioengineering10010100"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41573-019-0050-3","article-title":"Rethinking drug design in the artificial intelligence era","volume":"19","author":"Schneider","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0165-0173(97)00054-4","article-title":"Sodium channels as molecular targets for antiepileptic drugs","volume":"26","author":"Ragsdale","year":"1998","journal-title":"Brain Res. Rev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Grollemund, V., Pradat, P.-F., Querin, G., Delbot, F., Le Chat, G., Pradat-Peyre, J.-F., and Bede, P. (2019). Machine learning in amyotrophic lateral sclerosis: Achievements, pitfalls, and future directions. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.00135"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Vidovic, M., M\u00fcschen, L.H., Brakemeier, S., Machetanz, G., Naumann, M., and Castro-Gomez, S. (2023). Current state and future directions in the diagnosis of amyotrophic lateral sclerosis. Cells, 12.","DOI":"10.3390\/cells12050736"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Papaiz, F., Dourado Jr, M.E.T., Valentim, R.A.d.M., de Morais, A.H.F., and Arrais, J.P. (2022). Machine learning solutions applied to amyotrophic lateral sclerosis prognosis: A review. Front. Comput. Sci., 4.","DOI":"10.3389\/fcomp.2022.869140"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tips.2019.05.005","article-title":"Artificial intelligence for clinical trial design","volume":"40","author":"Harrer","year":"2019","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_97","unstructured":"Yue, T., Wang, Y., Zhang, L., Gu, C., Xue, H., Wang, W., Lyu, Q., and Dun, Y. (2018). Deep learning for genomics: A concise overview. arXiv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1145\/3546036","article-title":"Interpretable machine learning: Moving from mythos to diagnostics","volume":"65","author":"Chen","year":"2022","journal-title":"Commun. ACM"},{"key":"ref_99","unstructured":"Food, U., and Administration, D. (2021). Artificial Intelligence\/Machine Learning (AI\/ML)-Based Software as a Medical Device (Samd), Action Plan; FDA."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Giger, M.L., and Suzuki, K. (2008). Computer-aided diagnosis. Biomedical Information Technology, Elsevier.","DOI":"10.1016\/B978-012373583-6.50020-7"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2053951716679679","DOI":"10.1177\/2053951716679679","article-title":"The ethics of algorithms: Mapping the debate","volume":"3","author":"Mittelstadt","year":"2016","journal-title":"Big Data Soc."},{"key":"ref_102","unstructured":"Topol, E. (2019). Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again, Hachette UK."},{"key":"ref_103","first-page":"191","article-title":"Health insurance portability and accountability act of 1996","volume":"104","author":"Act","year":"1996","journal-title":"Public Law"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMp1714229","article-title":"Implementing machine learning in health care\u2014Addressing ethical challenges","volume":"378","author":"Char","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/M18-1990","article-title":"Ensuring fairness in machine learning to advance health equity","volume":"169","author":"Rajkomar","year":"2018","journal-title":"Ann. Intern. Med."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1041\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:09:29Z","timestamp":1760033369000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/1041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":105,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18071041"],"URL":"https:\/\/doi.org\/10.3390\/ph18071041","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}